ASRA

Asra Therapeutics is a precision medicine company dedicated to discovering and developing transformative therapies for patients with liver diseases, with an initial focus on Alpha-1 Antitrypsin Deficiency (AATD). The company leverages a proprietary platform to identify genetic modifiers that influence disease severity and progression, providing new avenues for therapeutic intervention. By understanding the molecular drivers of liver pathology, Asra aims to develop small molecule medicines that can halt or reverse organ damage. Headquartered in Boston and backed by Third Rock Ventures, the company integrates human genetics and advanced disease modeling to address significant unmet needs in hepatology. Their approach focuses on patients who carry genetic risks but exhibit varying clinical outcomes, aiming to unlock the potential of modifier-based drug discovery.